Can someone explain benefit of orphan drug status?
I mean if dasatinib, nilotinib, bosutinib, and very soon ponatinib all have orphan drug status in US and EU for CML then what is the benefit? Can there really be 7 years of market exclusivity in US and 10 years in EU for four relatively new drugs for the same indication?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.